Mesenteric Vascular Disease
Conditions
Keywords
Mesenteric arteries disease, Mesenteric Ischemia, Blood biomarkers
Brief summary
Vascular bowel disease remains a socially significant and potentially fatal condition (if it develops into AMI), primarily due to delayed diagnosis. Blood biomarkers are theoretically ideal for early risk stratification (like troponins in myocardial infarction). However, the existing evidence base is characterized by low quality and high heterogeneity, which hinders their use in clinical practice. Therefore, there is an urgent and unmet clinical need for high-quality, methodologically rigorous research to validate biomarkers in MI. A current study (MESMARK) is to be undertaken to identify combinations of biomarkers that can reliably identify mesenteric ischemia (MI) and distinguish between non-transmural and transmural clinical relevant ischemia.
Interventions
DIAGNOSTIC_TESTBlood samples
Blood samples as diagnostic tests are the only intervention in the trial
Sponsors
Belarusian State Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Blood samples is to be collected from study subjects
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* 18 years or older, all sex * Initial decision, the presence of angio-visualisation of the MA and suspicion of mesenteric arteries diseases * Patient's consent to participate in the study * No pregnancy, no history of major operations on MA, the gastrointestinal tract and digestive organs (except appendectomy, endoscopic polypectomy).
Exclusion criteria
* Consent declined by patient or relatives * Failure to meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Increasing in the level of mesenteric ischemia (MI) markers above the reference threshold level within 1 day after enrollment in the study | From enrollment to the 24 hours | Assessment of serum markers level is intended to identify reliable serum markers or the panel of them as biomarkers for the diagnosis of MI. The endpoint is "increasing in serum marker level above the threshold reference level within 24 hours of objectively suspected MI or not". Markers with elevated above the reference threshold level will be assessed individually and in combination (as a marker panel) later to calculate their sensitivity and specificity in diagnostic of MI. These markers include intestinal fatty acid-binding protein (I-FABP), alpha-glutathione S-transferase (α-GST), ischaemia-modified albumin (IMA), D-lactate, D-dimer, adropin, hypoxia-inducible factor (HIF-1α). |
Countries
Belarus
Contacts
CONTACTHleb But-Husaim, PhD
Outcome results
None listed